Agios sets out to raise $150M; AC Immune IPO sets valuation at $700M
In biotech, you raise money when you can. And just days after Agios $AGIO spelled out plans for a shot at two accelerated approval plans …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
